If management is not both competent and honest, a company is doomed to failure.
In my opinion, Pourhassan possesses neither of these qualities and, if not replaced, will lead the company into bankruptcy.
I base this opinion upon years of careful study and analysis.
Thus, I have been invested in Cytodyn for more than six years, having participated in numerous Paulson raises.
At one time, I had more than a million shares, and still own shares in the six figures.
During my six year journey with Cytodyn, I have closely watched, listened to, and even spoken with, Pourhassan.
I have watched as promise after Pourhassan promise has failed to come to fruition.
I was disgusted to discover that Pourhassan netted about $15 million from the sale of his stock, while telling the shareholders he was doing this for the benefit of the company.
I read with interest the ruling of the Delaware judge with respect to the stock issued to Pourhassan and Kelly, who strongly intimated it was improper for that stock to have been issued to them.
I have urged Pourhassan, many times, to show his support for, and belief in, the company by purchasing shares in the open market.
I have asked Pourhassan again, many times, why he did not purchase shares when, according to him, they were grossly undervalued.
Finally, I have read the unprecedented rebuke of Leronlimanab by the FDA that I found to be quite disturbing.
Based on all of this, and much more, it is my opinion that Pourhassan does not possess any of the qualities needed to effectively lead this company.
I will therefore be voting for the 13D slate, and will welcome a new CEO with open arms.
These are, of course, my opinions, and everyone should follow their own conscious.
LM
